Boston Scientific to Acquire Baylis Medical Company

October 6, 2021—Boston Scientific Corporation announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The transaction is anticipated to close in the first quarter of 2022, subject to customary closing conditions.

According to the company, the acquisition will expand Boston Scientific’s electrophysiology and structural heart product portfolios to include the radiofrequency NRG and VersaCross transseptal platforms as well as a family of guidewires, sheaths, and dilators used to support left heart access.

These platforms have advanced transseptal puncture and are clinically proven to enhance safety, efficacy, and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart, such as atrial fibrillation ablation, left atrial appendage closure (LAAC), and mitral valve interventions, noted Boston Scientific.

Baylis Medical Company received FDA 510(k) clearance for the NRG platform in 2008. The company received FDA 510(k) clearance for the VersaCross platform in 2020. These platforms are complemented by the company’s family of guidewires, sheaths, and dilators, which are designed for use in left-sided diagnostic, ablation, mitral, and LAAC procedures, noted the announcement.